Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GLP1R | P43220 | 8/20 | 0.36 |
| ▸ | TLR2 | O60603 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.30 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.30 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12196382 | 0.89 | MEN1 (0.38) | MEN1KMT2AGLP1RTLR2DGAT1 | |
| SCHEMBL13839054 | 0.87 | TLR2 (0.40) | MEN1KMT2AGLP1RTLR2SIRT6 | |
| SCHEMBL13839052 | 0.84 | SIRT6 (0.44) | MEN1KMT2AGLP1RTLR2SIRT6 | |
| SCHEMBL12196529 | 0.75 | MEN1 (0.43) | MEN1KMT2AGLP1RTLR2EPHX1 | |
| SCHEMBL12196491 | 0.75 | TLR2 (0.36) | MEN1KMT2AGLP1RTLR2SIRT6 | |
| SCHEMBL12766489 | 0.72 | SMN1; SMN2 (0.36) | KMT2ASIRT6SIRT1 | |
| SCHEMBL10132076 | 0.70 | METAP1 (0.36) | — | |
| SCHEMBL18760223 | 0.69 | SMN1; SMN2 (0.52) | EPHX1EPHX2 | |
| SCHEMBL16216473 | 0.69 | GLP1R (0.41) | MEN1KMT2AGLP1RTLR2EPHX1 | |
| SCHEMBL12196494 | 0.68 | MEN1 (0.38) | MEN1KMT2ATLR2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130079283-A1 | Erythropoitein Receptor Peptide Formulations and Uses | AFFYMAX, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-7919461-B2 | Utilizing amino acid sequences linked to polyethylene glycol as agonists; increasing red blood cell production; chronic kidney disease | AFFYMAX, INC. (US) | 2011-04-05 | — | — | US | disclosed |
| US-7528104-B2 | Peptides that bind to the erythropoietin receptor | AFFYMAX, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7414105-B2 | Peptide dimer bonded to polyethylene glycol through amide groups; insufficient or defective red blood cell production | AFFYMAX, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20080081783-A1 | ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES | AFFYMAX, INC. (US) | 2008-04-03 | — | — | US | disclosed |
| US-20070104704-A1 | Erythropoietin receptor peptide formulations and uses | AFFYMAX, INC. (US) | 2007-05-10 | — | — | US | disclosed |
| US-20070027074-A1 | Novel peptides that bind to the erythropoietin receptor | AFFYMAX, INC. (US) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079283-A1 | Erythropoitein Receptor Peptide Formulations and Uses | EPOR, MPL, PROKR1 | MEN1 1252/4885KMT2A 3761/4885GLP1R 26/4885 |
| US-20070027074-A1 | Novel peptides that bind to the erythropoietin receptor | EPOR, PROKR1, EDNRB | MEN1 3831/4885KMT2A 4517/4885GLP1R 53/4885 |
| US-20080081783-A1 | ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES | EPOR, PROKR1, PROKR2 | MEN1 2467/4885KMT2A 3618/4885GLP1R 11/4885 |
| US-20070104704-A1 | Erythropoietin receptor peptide formulations and uses | EPOR, PROKR1, PROKR2 | MEN1 2467/4885KMT2A 3618/4885GLP1R 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.